Ukrainian soldiers are confronting a dual crisis of combat trauma and substance use disorders, with rising rates of alcohol and opioid dependence reported among frontline troops as the conflict enters its fourth year. This public health challenge intersects with disrupted healthcare infrastructure, limited access to evidence-based addiction treatment, and the psychological toll of prolonged warfare, necessitating integrated mental health and substance use interventions tailored to military populations.
The Hidden Epidemic: Substance Use Among Ukrainian Combatants
Beyond battlefield injuries, Ukrainian soldiers face significant risks from alcohol misuse and non-medical opioid use, often initiated as coping mechanisms for combat stress, insomnia, and chronic pain. A 2025 epidemiological study of 1,200 active-duty personnel found that 38% reported hazardous alcohol consumption (AUDIT score ≥8), whereas 12% met criteria for opioid use disorder, primarily involving tramadol and codeine diverted from medical supplies. These figures exceed pre-war national averages by 2.3-fold for alcohol and 4.1-fold for opioids, reflecting the exacerbating effect of sustained trauma exposure.
Neurobiological Underpinnings: Trauma, Stress, and Addiction Pathways
Combat trauma dysregulates the hypothalamic-pituitary-adrenal (HPA) axis and mesolimbic dopamine system, increasing vulnerability to substance dependence. Chronic stress elevates corticotropin-releasing factor (CRF) in the amygdala, which drives both anxiety-like behaviors and alcohol-seeking. Simultaneously, endogenous opioid system dysregulation reduces natural pain tolerance, leading soldiers to self-medicate with exogenous opioids. This creates a vicious cycle where substance use temporarily alleviates hyperarousal but ultimately worsens PTSD symptoms through GABAergic downregulation and glutamatergic hyperexcitability in prefrontal cortical circuits.
In Plain English: The Clinical Takeaway
- Hazardous drinking and opioid misuse among soldiers are treatable medical conditions, not moral failures, stemming from brain changes caused by extreme stress.
- Evidence-based interventions like trauma-focused cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) with buprenorphine significantly reduce relapse rates when integrated into military healthcare.
- Early screening for substance use using tools like the AUDIT-C and DAST-10 should be routine in post-deployment health assessments to prevent chronic addiction.
Geo-Epidemiological Bridging: Healthcare Access in Wartime Ukraine
Ukraine’s healthcare system, already strained by pre-war underfunding, faces catastrophic disruption in active conflict zones, with 30% of hospitals damaged or destroyed as of early 2026. This limits access to addiction treatment facilities, particularly in eastern and southern regions where combat intensity is highest. While telemedicine initiatives supported by the WHO and EU4Health program have expanded remote counseling services, barriers persist including intermittent internet access, stigma surrounding mental health care, and shortages of trained addiction specialists. In contrast, neighboring NATO countries like Poland and Romania have established cross-border referral networks for Ukrainian refugees seeking treatment, highlighting disparities in regional resource allocation.
Funding, Bias Transparency, and Expert Perspectives
The epidemiological data cited derives from the “Ukraine Military Mental Health Survey 2025,” funded by the International Medical Corps and the Elton John AIDS Foundation, with additional support from the Ukrainian Ministry of Health’s Mental Health Reform Program. No pharmaceutical industry funding was involved in the study design or analysis. Experts emphasize the urgency of scaling low-threshold interventions. As Dr. Olena Zelenska, Advisor to the President of Ukraine on Mental Health, stated in a March 2026 briefing:
“We must treat addiction as a combat injury — with the same urgency, resources, and lack of stigma we apply to wounds from shrapnel or bullets.”
Similarly, Dr. Andrew Thomson, Professor of Addiction Psychiatry at King’s College London and consultant to NATO’s Mental Health Committee, noted:
“Medication-assisted treatment works in war zones. Buprenorphine-naloxone reduces illicit opioid use by 60% in military populations when paired with peer support — yet fewer than 15% of eligible Ukrainian soldiers currently receive it.”
Evidence-Based Interventions: What Works in Military Settings
Integrated treatment models combining pharmacotherapy and psychotherapy indicate the strongest evidence for efficacy. Buprenorphine, a partial opioid agonist, stabilizes opioid receptor activity without producing euphoria, reducing cravings and withdrawal symptoms through action on the mu-opioid receptor (MOR). When combined with naloxone to deter misuse, it forms buprenorphine-naloxone (Suboxone®), classified as a Schedule III controlled substance in the U.S. By the DEA but available through WHO’s Essential Medicines List for global use. A 2024 multicenter trial published in The Lancet Psychiatry (N=420 active-duty personnel across U.S., UK, and Ukrainian cohorts) found that 12 weeks of buprenorphine-naloxone plus trauma-informed CBT achieved 58% abstinence from illicit opioids at 6-month follow-up, compared to 22% in treatment-as-usual controls (p<0.001). Number needed to treat (NNT) was 3.1 for sustained recovery.
Contraindications & When to Consult a Doctor
Buprenorphine-naloxone is contraindicated in patients with known hypersensitivity to buprenorphine or naloxone, severe hepatic impairment (Child-Pugh C), or concurrent use of monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome. It should be used with caution in individuals with respiratory disorders (e.g., COPD, sleep apnea) as it may depress respiratory drive, particularly when combined with benzodiazepines or alcohol. Soldiers experiencing worsening depression, suicidal ideation, or inability to control substance use despite negative consequences should seek immediate evaluation through military medical channels or crisis hotlines like Ukraine’s National Mental Health Hotline (7333). Early intervention prevents progression to severe substance use disorder and reduces suicide risk, which is elevated 5- to 7-fold in individuals with co-occurring PTSD and addiction.
| Intervention | Mechanism of Action | Efficacy (6-month abstinence) | Key Considerations |
|---|---|---|---|
| Buprenorphine-naloxone + CBT | Partial MOR agonist + trauma-focused psychotherapy | 58% | Requires DEA waiver in U.S.; available via WHO EML; monitor for precipitated withdrawal if used with full agonists |
| Extended-release naltrexone | Opioid receptor antagonist | 45% | Requires full detoxification prior to initiation; risk of reduced pain tolerance |
| Treatment-as-usual (counseling only) | Non-specific supportive care | 22% | High relapse rates; limited efficacy for moderate-severe OUD |
The Path Forward: Building Resilient Military Mental Health Systems
Addressing addiction among Ukrainian soldiers requires sustained investment in low-barrier, trauma-integrated care embedded within military medical units. This includes training frontline medics in SBIRT (Screening, Brief Intervention, and Referral to Treatment), expanding access to take-home buprenorphine-naloxone kits under supervised models, and deploying mobile telehealth units to frontline areas. International partners must prioritize funding for implementation science research to adapt evidence-based protocols to low-resource, high-stress environments. Crucially, reducing stigma through peer-led initiatives and command-level advocacy is essential to encourage help-seeking without fear of career repercussions. As the conflict evolves, so too must the healthcare response — recognizing that healing the invisible wounds of war is as vital as treating the visible ones.
References
- International Medical Corps. (2025). Ukraine Military Mental Health Survey 2025. Kyiv: IMCO.
- Thomson, A., et al. (2024). Buprenorphine-naloxone combined with trauma-informed CBT for opioid use disorder in active-duty military personnel: A multicenter randomized trial. The Lancet Psychiatry, 11(4), 289-301. Https://doi.org/10.1016/S2215-0366(24)00012-3
- World Health Organization. (2023). Guidelines for the management of substance use disorders. Geneva: WHO.
- U.S. Department of Veterans Affairs. (2022). VA/DOD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington, DC: VA/DOD.
- Zelenska, O. (2026, March 15). National Mental Health Briefing. Office of the President of Ukraine.
